Comparison and suggestions on the efficacy of DaliRasheng (Keweike) for different types of insomnia

Daridorexant is a new type of oral dual-receptor melanin receptor antagonist (DORA). It mainly blocks hypnosis-related orexin neural pathways to help patients fall asleep quickly and extend deep sleep time. Compared with traditional benzodiazepines, Dalitraxen has low dependence and little impact on cognitive function after waking up, so it has obvious advantages in long-term insomnia management. This medicine is suitable for various types of insomnia, including difficulty falling asleep, maintenance insomnia and mixed insomnia.

For patients who mainly have difficulty falling asleep, DaliLasin can significantly shorten the sleep onset latency (sleep onset latency). Clinical studies have shown that most patients can noticeably speed up in falling asleep within 1 week after taking the drug for the first time, and the average time to fall asleep is shortened by about 20 to 30 minutes. This fast-acting feature makes it the preferred solution for patients who have difficulty falling asleep in the early stages, while keeping the number of nighttime awakenings low and improving overall sleep quality.

In patients who are prone to waking up at night or who suffer from maintenance insomnia, DaliRasen can effectively extend the total sleep time (TST), reduce the number of nighttime awakenings, and improve the symptoms of early awakening. Clinical data shows that after continuous use for 2 to 4 weeks, the total sleep time of patients with maintenance insomnia is increased by about 45 minutes on average, and the number of nighttime awakenings is significantly reduced. In addition, for mixed insomnia (both difficulty falling asleep and waking up at night), DaliRasen also shows good efficacy, taking into account both falling asleep and maintaining sleep, and overall improving sleep structure and subjective sleep experience.

In clinical application, for different types of insomnia, the dose of DaliRasen should be adjusted according to the symptom characteristics and the patient's daily routine. Patients with difficulty falling asleep can choose a dose as low as 10mg or 15mg. Patients with sleep maintenance or mixed type can use a dose of 20mg to balance falling asleep and maintaining sleep at night. Patients should follow a regular schedule while taking the medication, avoid excessive alcohol or caffeine intake, and regularly evaluate the efficacy and side effects. Overall, DaliRasen has considerable efficacy in treating different types of insomnia, and has good compliance and safety. It is an important choice in modern insomnia management.

Reference materials:https://www.drugs.com/